GYRE Valuation
Gyre Therapeutics Inc
$
7.890
- Overview
- Forecast
- Valuation
GYRE Relative Valuation
GYRE's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, GYRE is overvalued; if below, it's undervalued.
Historical Valuation
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
10.52
P/B
Median3y
-11.98
Median5y
-11.98
-0.85
FCF Yield
Median3y
0.18
Median5y
0.18
Competitors Valuation Multiple
The average P/S ratio for GYRE's competitors is 18.74, providing a benchmark for relative valuation. Gyre Therapeutics Inc Corp (GYRE) exhibits a P/S ratio of 5.56, which is -70.30% above the industry average. Given its robust revenue growth of -75.43%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
People Also Watch
SHLS
Shoals Technologies Group Inc
3.330
USD
+1.22%
CPF
Central Pacific Financial Corp
24.740
USD
-0.40%
BFST
Business First Bancshares Inc
22.320
USD
+0.45%
GSL
Global Ship Lease Inc
20.090
USD
-1.18%
LAC
Lithium Americas Corp
2.655
USD
+0.95%
MTAL
Metals Acquisition Ltd
8.730
USD
+1.87%
PLYM
Plymouth Industrial REIT Inc
14.245
USD
+0.67%
ARKO
Arko Corp.
3.950
USD
-0.75%
MLR
Miller Industries Inc
39.230
USD
-3.52%
AC
Associated Capital Group Inc
34.190
USD
-0.23%
FAQ
Is Gyre Therapeutics Inc (GYRE) currently overvalued or undervalued?
Gyre Therapeutics Inc (GYRE) is now in the Fair zone, suggesting that its current forward PS ratio of 5.56 is considered Fairly compared with the five-year average of 0.58. The fair price of Gyre Therapeutics Inc (GYRE) is between to according to relative valuation methord.
What is Gyre Therapeutics Inc (GYRE) fair value?
How does GYRE's valuation metrics compare to the industry average?
What is the current P/B ratio for Gyre Therapeutics Inc (GYRE) as of Apr 16 2025?
What is the current FCF Yield for Gyre Therapeutics Inc (GYRE) as of Apr 16 2025?
What is the current Forward P/E ratio for Gyre Therapeutics Inc (GYRE) as of Apr 16 2025?